Cellular Biomedicine Group (CBMG) to Present at the 9th Annual Biotech Showcase in San Francisco

Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Company has been selected to present at the 9th Annual Biotech Showcase to be held from January 9-11, 2017 in San Francisco, CA. The Company will present an update on its operations, activities and clinical research progress.

Conference:			9th Annual BioTech Showcase 2017
Date:			Tuesday, January 10, 2017
Time:			10:30 AM PST
Presenter:			Tony (Bizuo) Liu, Chief Executive Officer
Location:			Room 2 (Ballroom Level) Hilton San Francisco Union Square, 333 O'Farrell Street, San Francisco, CA
Live webcast:			https://event.webcasts.com/viewer/event.jsp?ei=1130607

Company management will attend the conference and be available for discussions. To arrange one-to-one meetings with management, please contact [e-mail]. The presented material will be available on the Company website following the presentations.

About Cellular Biomedicine Group (CBMG)Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com.

Forward-Looking StatementsStatements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contacts:
Sarah Kelly 
Director of Corporate Communications, CBMG
[phone]
[e-mail]

Vivian Chen
Managing Director Investor Relations, Grayling
[phone]
[e-mail]